Tocilizumab – interleukin 6 receptor inhibitor – a new therapeutic option in the treatment of rheumatoid arthritis

Magdalena Szmyrka-Kaczmarek; Piotr Wiland

eISSN: 2084-9834
ISSN: 0034-6233

Reumatologia/Rheumatology

Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

2/2009
vol. 47

Send email

Copy url:

abstract:

Review paper

Tocilizumab – interleukin 6 receptor inhibitor – a new therapeutic option in the treatment of rheumatoid arthritis

Magdalena Szmyrka-Kaczmarek

,

Piotr Wiland

Reumatologia 2009; 47, 2: 85–94

Online publish date: 2009/06/10

View full text Get citation

Interleukin 6 is a pleiotropic cytokine which regulates the innate and adaptive immune response, inflammation and acute phase response. It plays a significant role in various chronic inflammatory processes including rheumatoid arthritis. The inhibition of IL-6 signal transduction by monoclonal antibodies against IL-6 receptor is a new efficient and safe therapeutic method in rheumatoid arthritis

keywords:

interleukin 6, interleukin 6 receptor, tocilizumab, rheumatoid arthritis

EVENTS/KONFERENCJE

BOOKS/KSIĄŻKI

Tocilizumab – interleukin 6 receptor inhibitor – a new therapeutic option in the treatment of rheumatoid arthritis

Magdalena Szmyrka-Kaczmarek , Piotr Wiland

interleukin 6, interleukin 6 receptor, tocilizumab, rheumatoid arthritis

Magdalena Szmyrka-Kaczmarek

,

Piotr Wiland